UC Davis has an outstanding Movement Disorders Program that provides evaluation, treatment and management of a range of diseases that cause involuntary excessive movements or slow, awkward, deliberate movements.
Movement disorders and diseases we treat
- Parkinson's disease
- Huntington's disease
- Essential tremor
- Several other movement disorders
Our patients come from Northern California as well as neighboring states to receive the latest treatments, which include:
- Oral medication
- Botulinum toxin therapy
- DBS implantation and programming
In addition to patient care, our faculty members conduct both basic and clinical research aimed at developing new treatments for Parkinson’s disease, Huntington’s disease, and other movement disorders. (For more information about our research into Huntington's disease, please visit our HD Center of Excellence Research page.)
Some of our faculty conduct clinical trials as members of the Parkinson Study Group, an organization of researchers from the U.S. and Canada who are working to test new treatments for PD, as well as looking into the genetics of people who may be predisposed to develop it. Patients who would like to help in our ongoing research efforts may be able to participate in one of several clinical studies designed to improve medical knowledge about these conditions and to test potential new therapies. Current studies are described below:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"
For more information, enter NCT02453386 into the search box at www.clinicaltrials.gov.
Outpatient Physical Therapy Intervention in Subjects with Parkinson’s Disease Currently Using APOKYN®
For more information, enter NCT02549573 into the search box at www.clinicaltrials.gov.
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
For more information, enter NCT02202551 into the search box at www.clinicaltrials.gov.
A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy. Enrollment will start early 2016.
For more information, enter NCT02586623 into the search box at www.clinicaltrials.gov.
A randomized, double-blind, placebo-controlled trial of urate-elevating inosine treatment to slow clinical decline in early Parkinson’s disease. Expected to start mid-2016.
Planned future studies include:
REPsy-PD: Rivastigmine for Early Psychosis in patients with Parkinson's disease with normal cognition, mild cognitive impairment and dementia.
Gray Zone alleles for Fragile X-associated Tremor/Ataxia syndrome and the risk of Parkinson's disease.
If you are interested in participating or want more information about our clinical trials,
Rose Khalatyan at 916-734-6977, or by email at email@example.com